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Abstract
Background Efficacy, safety and pharmacokinetics of
simeprevir (TMC435), a once-daily, noncovalent, oral
hepatitis C virus (HCV) NS3/4A protease inhibitor, was
evaluated in combination with peginterferon a-2a/ribavirin
(PegIFNa-2a/RBV) for treatment-naı¨ve, HCV genotype 1-
infected patients in Japan.
Methods In a multicenter, randomized clinical trial in
Japan, ninety-two patients received either simeprevir (50 or
100 mg QD) for 12 or 24 weeks with PegIFNa-2a/RBV for
24 or 48 weeks (according to response-guided therapy [RGT]
criteria), or PegIFNa-2a/RBV for 48 weeks (PR48 group).
Results Compared with the PR48 group, plasma HCV
RNA reductions in the simeprevir groups were rapid and
more substantial (Week 4: -5.2, -5.2 and -2.9 log10IU/mL
for simeprevir 50 mg combined, 100 mg combined, and
PR48 groups, respectively). High rapid virologic response
rates (83, 90, and 8 % for simeprevir 50 mg combined, 100
mg combined, and PR48 groups, respectively) led to high
sustained virologic response rates (77–92 %, compared with
46 % for PR48). All but one of the simeprevir-treated
patients were eligible to complete treatment after 24 weeks
(RGT). Relapse rates in simeprevir-treated patients were low
(8–17 %, compared with 36 % for the PR48 group). There
were no notable differences in the safety profile between the
simeprevir and PR48 groups.
Conclusions The addition of simeprevir QD to PegIFNa-
2a/RBV, as compared with PegIFNa-2a/RBV alone,
demonstrated potent antiviral activity and significantly
improved the rates of sustained virologic response, with a
shortened 24-week treatment duration, in treatment-naive
patients infected with HCV genotype 1 in Japan. Sime-
previr was generally safe and well tolerated. (ClinicalTri-
als.gov number, NCT00996476).
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SAE Serious adverse event
SVR24 Sustained virologic response 24 weeks after
end of treatment
Introduction
The hepatitis C virus (HCV) is a leading cause of chronic
liver disease worldwide infecting an estimated 130–170
million people, or 2.2–3.0 % of the global population [1,
2]. In Japan, hepatocellular carcinoma (HCC) is one of the
most common causes of cancer mortality (incidence of 7 %
in Japan, compared with 1–4 % in Europe and the USA
[3]) and 79 % of HCC cases are due to HCV infection [4,
5]. An estimated 2 million Japanese people are infected,
70 % with HCV genotype 1b, 20 % with genotype 2a, and
the remainder with genotype 2b or other genotypes [6].
Until recently, the standard of care for the treatment of
chronic genotype 1 HCV infection was a combination of
peginterferon (PegIFNa-2a) and ribavirin (RBV) for
48 weeks or longer [2, 7–9]. However, the long treatment
duration is a substantial physical and mental burden for
patients, and rates of treatment discontinuation and dose
reduction due to adverse events (AEs) are high [10, 11].
Furthermore, sustained virologic response (SVR, defined as
undetectable HCV RNA at a given time point after the end of
treatment) is achieved in only 42–52 % of patients [10–12].
Novel, direct-acting antiviral agents (DAAs) are therefore
under development. Two first-generation HCV NS3/4A
protease inhibitors (PIs), boceprevir [13, 14] and telaprevir
[15, 16], have recently been approved for the treatment of
genotype 1-infected patients in the USA and Europe, and
telaprevir is also approved in Japan [17, 18]. The inclusion of
these agents in HCV treatment regimens has led to large
improvements in SVR rates, though these agents require
dosing three times daily (every 7-9 h) and their use is asso-
ciated with increased incidence and, in some cases, severity
of AEs such as anemia and rash [13, 16, 18–21].
Simeprevir (TMC435) is an investigational, once-daily
(QD) oral NS3/4A protease inhibitor currently under clin-
ical development globally. International Phase IIb trials of
simeprevir in combination with PegIFNa-2a/RBV for
treatment-naı¨ve and -experienced patients infected with
HCV genotype 1 demonstrated that simeprevir was gen-
erally well tolerated, had a pharmacokinetic profile that
supports QD dosing and resulted in high virologic response
rates [22–25].
In a Phase I study in 30 healthy Japanese adult male
volunteers living in the USA (TMC435-C109;
NCT00752544), simeprevir was generally well tolerated.
Simeprevir plasma exposures were higher in Japanese
healthy volunteers compared with Caucasian volunteers in
the TMC435-C101 study (NCT00938899) [26].
The Dose and duration Ranging study of Antiviral agent
TMC435 in Genotype One HCV treatment-Naı¨ve patients
(DRAGON; TMC435-C215) was a Phase II study con-
ducted across Japan to evaluate the efficacy, safety and
pharmacokinetics of simeprevir and PegIFNa-2a/RBV in
treatment-naı¨ve, HCV-infected patients. Based on the
higher exposure of simeprevir in Japanese versus Cauca-
sian healthy volunteers demonstrated in the Phase I study,
simeprevir doses of 50 and 100 mg QD were selected for
evaluation in this dose-ranging, Japanese Phase II study.
Methods
Patients
Patients recruited to the DRAGON study were treatment-
naı¨ve, chronically infected with genotype 1 HCV, aged
20–70 years and had plasma levels of HCV RNA
C5.0 log10 IU/mL at screening.
Key exclusion criteria included: (1) presence of liver
cirrhosis or hepatic failure, or other liver disease, (2)
infection/co-infection with HIV-1, HIV-2, hepatitis B or
nongenotype 1 HCV, (3) malignant tumor within 5 years
prior to study, (4) HCC, (5) meeting conditions that
required caution with PegIFNa-2a or RBV treatment, (6)
any clinically significant disease, (7) organ transplant, and
(8) defined laboratory abnormalities during screening.
Study design
The DRAGON study was a multicenter, randomized, open-
label, parallel group comparison study performed to evaluate
the efficacy, safety and pharmacokinetics of simeprevir in
combination with PegIFNa-2a/RBV in treatment-naı¨ve
patients with chronic genotype 1 HCV infection. The study
was performed from July 6, 2009, to April 1, 2011, in
accordance with the Declaration of Helsinki, and was con-
sistent with Good Clinical Practice guidelines and applicable
regulatory requirements. The study protocol and amend-
ments were reviewed by Institutional Review Boards and
each patient provided written informed consent.
Eligible patients were randomized to one of five treat-
ment groups (SMV12/PR24 50 mg, SMV24/PR24 50 mg,
SMV12/PR24 100 mg, SMV24/PR24 100 mg and PR48)
in a 2:1:2:1:1 ratio. In the SMV12/PR24 50 mg and
SMV12/PR24 100 mg groups, patients received simeprevir
(50 or 100 mg QD, respectively) combined with PegIFNa-
2a/RBV for 12 weeks, followed by PegIFNa-2a/RBV for
12 weeks. In the SMV24/PR24 50 mg and SMV24/PR24
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100 mg groups, patients received simeprevir (50 or
100 mg QD, respectively) combined with PegIFNa-2a/
RBV for 24 weeks. In these four groups, at week 24,
patients either stopped or continued treatment with Peg-
IFNa-2a/RBV up to week 48, according to response-guided
therapy (RGT) criteria (stop treatment if plasma HCV RNA
\1.4 log10 IU/mL at week 4 and undetectable at weeks 12,
16 and 20, otherwise continuing PegIFNa-2a/RBV to week
48). In the PR48 group, criteria were not applied; patients
received PegIFNa-2a/RBV for 48 weeks.
Major efficacy endpoints included the proportion of
patients with undetectable plasma HCV RNA 24 weeks
after the end of treatment (SVR24). Other efficacy end-
points included the proportion of patients with undetectable
plasma HCV RNA at week 4 (rapid virologic response;
RVR) or week 12 (complete early virologic response,
cEVR) and change in plasma HCV RNA level from
baseline to week 4 of treatment. Incidence of viral break-
through (increase of[1 log10 IU/mL in plasma HCV RNA
level from the lowest level reached, or plasma HCV RNA
level of [2.0 log10 IU/mL in patients whose plasma
HCV RNA level had previously been below 1.4 log10 IU/
mL or undetectable), viral relapse (detectable plasma HCV
RNA during the post-treatment follow-up period in patients
who had undetectable plasma HCV RNA at the end of
treatment) and the viral NS3 sequence were also assessed.
According to predefined virologic stopping rules,
patients in the simeprevir groups discontinued simeprevir
and continued PegIFNa-2a/RBV if viral breakthrough
occurred during the first 24 weeks, and stopped all treat-
ment if the decrease in plasma HCV RNA from baseline to
week 12 was \2 log10 IU/mL, or plasma HCV RNA level
at week 24 was C1.2 log10 IU/mL.
The population-based sequencing assay to determine
HCV NS3/4A sequence based on the standard Sanger
sequencing method was performed for patients with viral
breakthrough and viral relapse. Sequencing data were
reported as amino acid changes from Con1 (GenBank
accession number AJ238799) or H77 (GenBank accession
number AF009606) for genotype 1b and 1a/others,
respectively.
Safety endpoints included the frequency and severity of
AEs including serious AEs (SAEs), incidence of discon-
tinuation of study drugs due to AEs, and changes in clinical
laboratory test values.
Treatment administration
Simeprevir was administered orally at a dose of 50 or
100 mg as a single capsule QD. No simeprevir dose
reduction was permitted. PegIFNa-2a (Pegasys, Chugai)
was administered as a subcutaneous injection (180 lg once
weekly) and RBV (Copegus, Chugai) as oral tablets
(600–1000 mg total daily dose, depending on body weight)
in accordance with the manufacturer’s prescribing infor-
mation for both medications. Patients were hospitalized for
a minimum of 1 week, starting on the first day that sime-
previr and PegIFNa-2a/RBV were administered. Treatment
of anemia with erythropoietin was not permitted in the
study.
Measurements
Plasma HCV RNA was quantified upon screening, at
baseline, at 4 and 8 h on day 1, on day 3, at weeks 1, 2, 3,
4, 6, 8, 12, 16, 20 and 24 (all patients), and weeks 28, 36
and 48 (patients stopping PegIFNa-2a/RBV at week 24) or
weeks 28, 36, 42, 48, 52, 60 and 72 (patients receiving
PegIFNa-2a/RBV until week 48), using the Roche CO-
BAS TaqMan HCV Auto assay system (lower limit of
quantification [LLOQ] 15 IU/mL, equivalent to 1.2
log10 IU/mL). Plasma HCV RNA below the LLOQ was
either assigned as ‘HCV RNA \1.2 log10 IU/mL detect-
able’ if traces of HCV RNA were detected, or ‘undetect-
able HCV RNA’ if no HCV RNA was detected. Alanine
aminotransferase (ALT) was quantified at baseline and
weeks 1, 2, 4, 6, 8, 12, 16, 20 and 24 (all patients), and
weeks 28 and 48 (patients stopping at week 24), or weeks
36, 42, 48, 52 and 72 (patients receiving PegIFNa-2a/RBV
until week 48).
Laboratory test values, results of vital sign assessment
and presence or absence of electrocardiogram abnormali-
ties were recorded at screening and at regular intervals
throughout treatment and the post-treatment follow-up
period. AEs were recorded throughout the study period.
Statistical analysis
Efficacy analyses were performed on the full analysis set
(FAS; all randomized patients with post-baseline efficacy
assessment data). For virologic responses (RVR, cEVR and
SVR24), rates were summarized for the combined sime-
previr 50 mg (i.e. SMV12/PR24 50 mg and SMV24/PR24
50 mg groups pooled) and 100 mg (i.e. SMV12/PR24
100 mg and SMV24/PR24 100 mg groups pooled) groups,
and compared with that of the PR48 group. In addition, for
SVR24, rates were calculated for each of the five treatment
groups. The change in HCV RNA from baseline to week 4
was assessed using analysis of covariance (ANCOVA),
with the dose group as a factor and plasma HCV RNA at
baseline as a covariate, to calculate the least-squares (LS)
means and two-tailed corresponding 95 % confidence
intervals (CIs). These were calculated for change from
baseline for the combined simeprevir 50 mg or combined
simeprevir 100 mg groups and the PR48 group, and the
differences between groups. Fisher’s exact test was
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performed to compare RVR and cEVR between the com-
bined simeprevir groups and the PR48 group.
A mutation was considered as emerging at a specific
time point if the amino acid at a given position was absent
at baseline and present at that time point. Incidence of
emergent mutations at the time of viral breakthrough or
relapse was summarized.
The proportion of patients displaying ALT within the
normal limits was summarized for all patients in the
combined simeprevir groups and for the PR48 group.
Incidence of AEs and other safety endpoints were analyzed
for all patients who received at least one dose of medica-
tion and were summarized per treatment group.
Results
Patient disposition and baseline characteristics
In total, 116 patients were screened and 93 were random-
ized to treatment groups, of whom 92 received at least one
dose of a study drug (Supplementary Fig. 1). Ninety-one
percent of the patients completed the study. The main
reasons for study discontinuation were withdrawal of
consent (5 %) and occurrence of AEs (2 %). Out of seven
patients who discontinued from the study during the post-
treatment follow-up period, five patients dropped out due to
withdrawal of consent, and two (1 in SMV12/PR24 100 mg
group, 1 in PR48 group) due to AEs.
In the simeprevir groups, nine patients permanently
discontinued all treatment due to AEs (8/79, 10 %) or
virologic stopping criteria (1/79, 1.3 %). In the PR48
group, three patients permanently discontinued all treat-
ment due to AEs (n = 2) or another reason (n = 1).
There were no notable differences in baseline demo-
graphic characteristics between treatment groups (Table 1).
Approximately half of the patients (39 to 62 %) were male,
with a median age of 54 years (range 20–69 years) and
median body weight of 58 kg (range 40–85 kg). All
patients were infected with HCV genotype 1b and the
median baseline HCV RNA was 6.3 log10 IU/mL (range
4.5–7.0 log10 IU/mL). A total of 7 % of patients displayed




During the first 3–7 days of simeprevir administration, an
initial rapid reduction in plasma HCV RNA was evident in
all simeprevir groups (Fig. 1). For analysis of the impact of
simeprevir dose with regards to on-treatment virologic
response, data were pooled by dose group (simeprevir
50 mg groups combined and 100 mg groups combined;
Table 2).
The mean HCV RNA change from baseline to week 4
was significantly greater in the simeprevir combined 50
and 100 mg groups than in the PR48 group; LS mean
differences from the PR48 group were 2.4 for both sime-
previr 50 mg combined and 100 mg combined [both of the
least-squares mean difference values (95 % confidence
interval) were below zero].
The majority of patients in the simeprevir 50 mg com-
bined and 100 mg combined groups achieved RVR and
cEVR (83–90 and 92–98 %, respectively), compared with
rates of 8 and 54 %, respectively, in the PR48 group.
Sustained virologic response
The SVR24 rate was higher in the simeprevir groups than
in the PR48 group, with rates of 78, 77, 77, 92 and 46 in the
SMV12/PR24 50 mg, SMV24/PR24 50 mg, SMV12/PR24
100 mg, SMV24/PR24 100 mg and PR48 groups, respec-
tively (Table 2; Fig. 2).
All patients in the simeprevir groups, except for one
patient in the SMV12/PR24 100 mg group, successfully
completed treatment at week 24, as they met the RGT
criteria. Among these patients, SVR24 rates ranged from
83 to 90 %.
All seven patients who discontinued the study during the
follow-up period were classified as non-SVR, although four
out of the seven patients had undetectable HCV RNA at the
last visit before withdrawal.
Viral breakthrough, viral relapse or treatment failure
One patient in the SMV12/PR24 50 mg group experienced
viral breakthrough at week 20 after the HCV RNA level
became undetectable from weeks 3 to 16. This patient had
viral breakthrough during treatment with PegIFNa-2a/
RBV, after the completion of triple therapy. No viral
breakthrough was reported in the other simeprevir groups
or the PR48 group.
Compared to the PR48 group (36 %), viral relapse rates
were apparently lower in the simeprevir groups regardless
of dose or duration (15, 17, 15 and 8 % in the SMV12/
PR24 50 mg, SMV24/PR24 50 mg, SMV12/PR24 100 mg,
and SMV24/PR24 100 mg group, respectively) (Table 2).
Among the patients in the simeprevir treatment groups,
20 % (16/79) did not achieve SVR24. The reasons for this
were detectable HCV RNA at the end of treatment (two
patients), viral relapse (11 patients), or missing HCV RNA
results for patients at 24 weeks after they had achieved
undetectable levels at the end of treatment (three patients).
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Viral population sequencing
No emerging mutations were observed in the selected HCV
NS3 protease domain in the patient with viral break-
through. Paired HCV NS3 sequence information (at base-
line and time of relapse) was available for 10/11
simeprevir-treated relapsers, and emerging mutations in the
NS3 protease domain (Q80R, R155Q, D169A, C, E, H and/
or V, alone or in combination) were detected in six of these
ten patients.
Alanine aminotransferase
The proportion of simeprevir-treated patients who had
ALT levels within the normal limit had increased from
57 % at baseline to 92 % at the end of treatment (per
protocol analysis).
Safety
The rates of simeprevir and PegIFNa-2a/RBV discontinu-
ation and PegIFNa-2a/RBV dose modification due to AEs
were similar between the simeprevir groups and the PR48
group.
There was one death reported due to cerebral infarction
in the SMV12/PR24 100 mg group. The patient was a
64-year-old female with hypertension but no other notable
medical history. The death occurred approximately
3 weeks after the end of treatment and was therefore
considered to be unrelated to simeprevir and PegIFNa-2a/
RBV.
A summary of AEs is shown in Table 3. There were no
clinically relevant differences in the incidence of AEs
across the groups and the majority of AEs were of grade 1
or 2 in severity according to the WHO toxicity grading
predefined in the study protocol. Rash and arthralgia,
which were slightly higher ([15 % numerical difference)
in the simeprevir groups than in the PR48 group, were also
grade 1 or 2 in severity.
For protocol-predefined rash/cutaneous reactions
(except for pruritus without visible skin findings) consid-
ered by the investigator to be caused by any medication,
the incidence rate was similar between the simeprevir
groups and the PR48 group, with no notable differences
across the simeprevir groups and with no grade 3 or 4
events, such as Stevens-Johnson syndrome or toxic epi-
dermal necrosis, reported (Table 3). As for pruritus, which
Table 1 Patient demographics and baseline characteristics (safety population)
SMV12/PR24
50 mg (n = 27)
SMV24/PR24
50 mg (n = 13)
SMV12/PR24
100 mg (n = 26)
SMV24/PR24





Male, n (%) 12 (44) 6 (46) 10 (39) 8 (62) 7 (54) 43 (47)
Age, years, median (range) 53 (31–67) 48 (34–67) 56 (22–69) 54 (28–68) 54 (20–66) 54 (20–69)
Age B 65 years, n (%) 25 (93) 12 (92) 24 (92) 11 (85) 12 (92) 84 (91)
Weight, kg, median (range) 56 (40–81) 58 (44–80) 56 (44–85) 59 (46–83) 59 (45–81) 58 (40–85)
Baseline HCV RNA, log10 IU/mL,
median (range)
6.5 (4.5–6.9) 6.2 (5.3–6.7) 6.4 (5.2–6.9) 6.5 (5.8–7.0) 6.0 (5.1–6.9) 6.3 (4.5–7.0)
Genotype 1b, n (%) 27 (100) 13 (100) 26 (100) 13 (100) 13 (100) 92 (100)
Metavir fibrosis stage, n (%)
0: No fibrosis 0 0 2 (8) 2 (15) 1 (8) 5 (5)
1: Periportal fibrosis expansion 18 (67) 8 (62) 16 (62) 6 (46) 8 (62) 56 (61)
2: P-P septae ([1 septum) 7 (26) 3 (23) 8 (31) 4 (31) 3 (23) 25 (27)
3: P-C septae 2 (7) 2 (15) 0 1 (8) 1 (8) 6 (7)
4: Cirrhosis 0 0 0 0 0 0
All randomized patients who received any amount of study drug
P-P portal–portal, P-C portal-central
Fig. 1 Mean change from baseline in plasma HCV RNA through
week 24. HCV hepatitis C virus, PR peginterferon ? ribavirin, SD
standard deviation, SMV simeprevir
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was reported in 19 % of the simeprevir-treated patients
(compared to none in the PR group), all events were grade
1 or 2 in severity.
Incidences of anemia and decreased hemoglobin were
similar in the simeprevir groups and the PR48 group, as
were the rates of discontinuation and RBV dose reduction
due to these two AEs. All were grade 1 or 2 and no notable
differences were reported across the simeprevir groups. Of
note, treatment with erythropoietin was not permitted in the
study. Changes in hemoglobin levels from baseline were
also similar across the groups and none of the patients had
values \8 g/dL (Fig. 3a).
Mild and transient increases in bilirubin levels (direct
and indirect) were observed in the simeprevir groups dur-
ing the first 2 weeks. Mean bilirubin values stabilized or
decreased during continued treatment and returned to
baseline values after week 12 in the SMV12/PR24 groups
and week 24 in the SMV24/PR24 groups (Fig. 3b). These
changes were not associated with increases in the labora-
tory parameters for ALT or aspartate aminotransferase.
Four simeprevir-treated patients experienced grade 3
(2.6–5.0 mg/dL) or 4 ([5.0 mg/dL) total bilirubin eleva-
tions during weeks 1 to 2 of treatment (the ratio direct/total
bilirubin at the time point of the highest bilirubin value in
these four patients were 26.5, 31.6, 60.7 and 17.5 %,
respectively) and discontinued simeprevir in accordance
with the treatment discontinuation criteria, which were
predefined in the study protocol. All of these bilirubin
elevations began to decrease before or immediately after
the end of simeprevir treatment and returned to baseline
Table 2 On-treatment and post-treatment virologic response (full analysis set)
n/N (%) SMV 50 mg
combined (n = 40)
SMV 100 mg
combined (n = 39)
PR48 (control)
(n = 13)
Undetectable HCV RNA at week 2 11/39 (28) 17/39 (44) 0/13 (0)
LS mean change in plasma HCV RNA
from baseline at week 4 (95 % CI)a
-5.2 (-5.4, -5.0) -5.2 (-5.4, -5.0) -2.9 (-3.2, -2.5)
LS mean change of difference in plasma
HCV RNA from baseline at week 4 (95 % CI)b
-2.4 (-2.7, -2.0) -2.4 (-2.8, -2.0)
RVR 33/40 (83) 35/39 (90) 1/13 (8)
cEVR 39/40 (98*) 36/39 (92*) 7/13 (54)
SMV12/PR24
50 mg (n = 27)
SMV24/PR24
50 mg (n = 13)
SMV12/PR24
100 mg (n = 26)
SMV24/PR24




All patients 21/27 (78) 10/13 (77) 20/26 (77) 12/13 (92) 6/13 (46)
Patients who completed treatment at week 24c 20/24 (83) 9/10 (90) 18/20 (90) 9/10 (90)
Viral relapsed 4/26 (15) 2/12 (17) 4/26 (15) 1/13 (8) 4/11 (36)
a Least-squares mean change from baseline and their 95 % confidence intervals for each dose group
b Difference in least-squares mean change from baseline from PR48 control and their 95 % confidence intervals for each dose group from
ANCOVA model
c Patients who completed treatment at week 24 as per RGT, excluding patients who discontinued treatment before week 24
d The denominator is the number of patients with undetectable HCV RNA at the end of treatment
cEVR complete early virologic response, undetectable HCV RNA at week 12 in treatment period, HCV hepatitis C virus, PR pegylated interferon
alpha-2a and ribavirin, RVR rapid virologic response undetectable HCV RNA at week 4 of treatment, SVR24 sustained virologic response
24 weeks after the end of treatment
* P B 0.05 vs PR48 group; Fisher’s exact test
Fig. 2 Sustained virologic response rates (SVR24). PR peginterfer-
on ? ribavirin, SMV simeprevir
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Table 3 Summary of adverse events and changes in hemoglobin and total bilirubin levels across all treatment groups (safety population)
n (%) SMV12/PR24
50 mg (n = 27)
SMV24/PR24
50 mg (n = 13)
SMV12/PR24
100 mg (n = 26)
SMV24/PR24






Discontinuation of all treatment due
to adverse eventa
1 (4) 3 (23) 3 (12) 1 (8) 8 (10) 2 (15)
Discontinuation of simeprevir only
due to adverse event
1 (4) 0 3 (12) 2 (15) 6 (8)
Dose modification of PegIFNa-2a
or RBV due to adverse event
17 (63) 8 (62) 21 (81) 12 (92) 58 (73) 11 (85)
Any serious adverse event 0 1 (8) 3 (12) 1 (8) 5 (6) 0
Deathb 0 0 1 (8) 0 1 (1) 0
Common adverse eventsc
White blood cell count decreased 16 (59) 10 (77) 15 (58) 12 (92) 53 (67) 10 (77)
Malaise 17 (63) 8 (62) 16 (62) 7 (54) 48 (61) 8 (62)
Neutrophil count decreased 12 (44) 10 (77) 14 (54) 12 (92) 48 (61) 9 (69)
Rash 17 (63) 8 (62) 15 (58) 8 (62) 48 (61) 6 (46)
Pyrexia 18 (67) 7 (54) 10 (39) 7 (54) 42 (53) 7 (54)
Headache 14 (52) 8 (62) 13 (50) 6 (46) 41 (52) 8 (62)
Hemoglobin decreased 8 (30) 7 (54) 12 (46) 7 (54) 34 (43) 6 (46)
Arthralgia 9 (33) 6 (46) 7 (27) 5 (39) 27 (34) 2 (15)
Alopecia 11 (41) 5 (39) 6 (23) 3 (23) 25 (32) 6 (46)
Anemia 8 (30) 5 (39) 6 (23) 5 (39) 24 (30) 5 (39)
Protocol predefined rash/cutaneous
reactionsd
21 (78) 8 (62) 18 (69) 8 (62) 55 (70) 8 (62)
Grade 1 or 2 21 (78) 8 (62) 18 (69) 8 (62) 55 (70) 8 (62)
Grade 3 or 4e 0 0 0 0 0 0
Hemoglobin and total bilirubin levels by gradef
Hemoglobin levels
Grade 1 (9.5–10.5 g/dL) 9 (33) 4 (31) 9 (35) 5 (39) 27 (34) 8 (62)
Grade 2 (8.0–9.4 g/dL) 5 (19) 4 (31) 8 (31) 6 (46) 23 (29) 3 (23)
Grade 3 (6.5–7.9 g/dL) or 4
(\6.5 g/dL)
0 0 0 0 0 0
Total bilirubin levels
Grade 1 (1.2–1.5 mg/dL) 10 (37) 4 (31) 10 (39) 6 (46) 30 (38) 2 (15)
Grade 2 (1.6–2.5 mg/dL) 3 (11) 3 (23) 8 (31) 2 (15) 16 (20) 1 (8)
Grade 3 (2.6–5.0 mg/dL) 1 (4) 0 2 (8) 0 3 (4) 0
Grade 4 ([5.0 mg/dL) 0 0 0 1 (8) 1 (1) 0
All randomized patients who received any amount of investigational drug
PegIFNa-2a peginterferon alpha-2a, RBV ribavirin
a Patients who discontinued PegIFNa-2a/RBV treatment regardless of completion or discontinuation of simeprevir
b There was one death by cerebral infarction in the SMV12/PR24 100 mg group, which occurred 3 weeks after the end of treatment and was
considered to be unrelated to the study medication
c Common adverse events were those classified as occurring with an incidence of [30 % of patients in all the simeprevir groups
d Rash/cutaneous reaction (except for pruritus without visible skin finding), which is considered to have a relationship of causality to any
medication
e Rashes with some characteristics, such as vesiculation, moist desquamation or ulceration were categorized as grade 3. Exfoliative dermatitis,
mucous membrane involvement, erythema multiforme exudativum, Stevens–Johnson syndrome or toxic epidermal necrosis were categorized as
grade 4
f According to modified World Health Organization toxicity grades. The worst grade during the treatment period for each patient was identified
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after the end of simeprevir treatment. No particular chan-
ges (elevations) in other hepatic parameters or any clini-
cally relevant symptoms were reported in these patients.
No other clinically significant differences in laboratory
parameters between the simeprevir groups and the PR48
group were observed.
Discussion
This study was the first in treatment-naı¨ve Asian patients
chronically infected with HCV genotype 1 and with high
viral load, to investigate the efficacy, safety and pharma-
cokinetics of simeprevir as part of a treatment regimen
including PegIFNa-2a and RBV. In this study, all patients
were infected with HCV genotype 1b, reflecting the high
prevalence of this subtype in Japan.
Results of the study indicated that once-daily simeprevir
(50 and 100 mg) in combination with PegIFNa-2a/RBV
significantly improved the SVR24 rate compared with
PegIFNa-2a/RBV alone in this patient population.
In this study, an RGT strategy was employed to allow
individualized shortening of PegIFNa/RBV treatment
duration to 24 weeks, based on early viral kinetics.
According to the RGT criteria, the majority of simeprevir
patients were eligible to stop all treatment at week 24.
Furthermore, these patients had high SVR24 rates
(83–90 %). This indicates that an RGT approach is also
beneficial for patients in Japan. Shorter overall treatment
duration is highly desirable as it reduces the length of
exposure to PegIFNa-2a/RBV, thereby potentially reduc-
ing the duration of AEs experienced by the patient, and is
also a cost-effective alternative to standard-duration Peg-
IFNa/RBV therapy [27].
During the first 3 days of dosing, both 50 and 100 mg
doses of simeprevir demonstrated an initial rapid reduction
in HCV RNA. Subsequent reduction in HCV RNA was
less pronounced, and by week 4, the LS mean HCV RNA
decline from baseline was -5.2 log10 IU/mL in both the
simeprevir 50 mg combined and 100 mg combined groups,
compared with -2.9 log10 IU/mL in the PR48 group. This
biphasic reduction in HCV RNA was consistent with viral
kinetics observed in a previous proof-of-concept simepre-
vir study (OPERA-1) [23] and other potent DAAs. In all
simeprevir groups, RVR was highly predictive of SVR.
Following high RVR rates (83–90 %, compared with 8 %
in the PR48 group), simeprevir-treated patients achieved
high SVR24 rates (77–92 %, compared with 46 % in the
PR48 group), accompanied by low rates of viral relapse
(8–17 %, compared with 36 % in the PR48 group). The
response rates in the PR48 group are consistent with pre-
vious reports [18, 22, 28].
No viral breakthrough was reported in the simeprevir
100 mg groups during the treatment period. In addition, the
on-treatment virologic response rate in the early treatment
phase (weeks 2 to 4) was slightly higher in the simeprevir
combined 100 mg group compared with the combined
50 mg group (e.g., 44 % of the patients in the simeprevir
100 mg group had undetectable HCV RNA, versus 28 % in
the simeprevir 50 mg group at week 2). The on-treatment
response was not affected by the duration of simeprevir
treatment across dose group (RVR rate of 85, 77, 89 and
92 %; cEVR rate of 100, 92, 89 and 100 %, in the SMV12/
PR24 50 mg, SMV24/PR24 50 mg, SMV12/PR24 100 mg
and SMV24/PR24 100 mg groups, respectively), and no
clear relationship between relapse rate and duration of
simeprevir treatment was observed. Therefore, the sime-
previr 100 mg dose with a 12-week duration as triple
therapy has been selected to be taken forward into Phase III
trials.
Fig. 3 Mean hemoglobin and total bilirubin in patient plasma
through week 48. Total bilirubin ULN = 17.1 lmol/L. Scr screening
visit, BL baseline visit, PR peginterferon ? ribavirin, SD standard
deviation, SMV simeprevir, ULN upper limit of normal
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In addition to the notable virologic response, the study
demonstrated greater increases from baseline to the end of
treatment in the proportion of simeprevir-treated patients
(per protocol population) with normal ALT levels.
Overall, these results are consistent with previous sim-
eprevir trials which investigated HCV genotype 1-infected,
treatment-naı¨ve patients, conducted mainly in the USA and
Europe [23].
In simeprevir-treated patients with viral relapse for
whom sequence information was available, emerging
mutations in the NS3 protease domain (Q80R, R155Q,
D168A/C/E/H and V, alone or in combination) were
detected around the time of viral relapse in 6/10 patients.
Mutations at these positions have been previously identi-
fied in vitro [29]. Considering the dominance of the HCV
genotype 1b in Japan, further evaluation of emerging
mutations is required.
There were no notable differences in incidence of AEs
or discontinuations due to AEs between groups receiving
triple therapy of simeprevir with PegIFNa-2a/RBV and
those receiving PegIFNa-2a/RBV alone. In contrast to the
first-generation PIs [13, 16, 19–21], no severe anemia or
severe rash/cutaneous reactions (including, though not
limited to, Stevens-Johnson syndrome or toxic epidermal
necrosis) were reported in this study. Except for bilirubin
levels, there were no significant changes in laboratory
values including hemoglobin, neutrophil count and platelet
count. Mild, transient increases in bilirubin (direct, indirect
and total) levels were observed in simeprevir-treated
patients, though these were not clinically significant or
accompanied by increases in other hepatic function
parameters. These bilirubin level elevations were grade 3
(2.6–5.0 mg/dL) or 4 ([5.0 mg/dL) in four simeprevir-
treated patients, which led to the discontinuation of sime-
previr in these individuals. The bilirubin levels began to
decrease before the end of simeprevir treatment and
returned to baseline after the end of simeprevir treatment.
In vitro studies indicated that this may be due to the inhi-
bition of OATP1B1 and MRP2 transporters by simeprevir,
as both have a role in bilirubin clearance [30]. However, it
is not anticipated that inhibition of these transporters will
affect dosing, efficacy or safety in ongoing studies.
In conclusion, in Japanese treatment-naı¨ve patients
infected with HCV genotype 1b with high viral load,
treatment with oral, once-daily simeprevir in combination
with PegIFNa-2a and RBV, regardless of simeprevir dose
regimen (50 or 100 mg QD, for 12 or 24 weeks), demon-
strated potent antiviral activity and high SVR rates, and
shortened the overall treatment duration in the majority of
patients. Simeprevir was well tolerated, with no additional
side effects or incremental adverse events. The mild and
reversible bilirubin elevation was asymptomatic and not
accompanied by elevation of other hepatic parameters.
Novel DAAs are expected to continue the improvement
of HCV treatment (i.e., further improved safety profile,
more convenient dosing regimens, and reduced resistance),
started by the addition of the first generation of protease
inhibitors to PegIFN/RBV combination therapy. Based on
the data provided by this Phase II DRAGON study, the
Phase III CONCERTO trials will shed further light on the
treatment of chronic HCV genotype-1 infection in treat-
ment-naı¨ve and -experienced patients in Japan.
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